In this “marquee” article in Scientific American, Kevin Strange, Ph.D., and Viravuth Yin, Ph.D., write about the discovery of MSI-1436, a regenerative medicine drug candidate to regenerate heart muscle tissue after a heart attack. Strange is the co-founder, president and CEO of Novo Biosciences and the former president of the MDI Biological Laboratory; Yin is the co-founder and chief scientific officer of Novo and an associate professor at the MDI Biological Laboratory.
In this blog about the April edition of Scientific American, editor-in-chief Mariette DiChristina promos an article, “A Shot at Regeneration,” about a regenerative medicine drug candidate, MSI-1436, developed at the MDI Biological Laboratory to treat heart attack patients after a heart attack.
The MDI Biological Laboratory in Bar Harbor, Maine, has announced that it will offer a one-week intensive course May 27 through June 2, 2018 entitled “Applications of Organoid Technology” in partnership with Hubrecht Organoid Technology (The HUB), a non-profit organization based in Utrecht, Netherlands.
Researchers at the MDI Biological Laboratory have been using animal models beyond the well-known laboratory mouse for decades. Now, the use of diverse model organisms to explore human disease is truly starting to gain the recognition it deserves as a scientific approach.
A leader in regenerative medicine research will discuss the future of the field in the last of three public lectures in Maren Auditorium at the MDI Biological Laboratory on Wednesday, Aug. 9, at 7 p.m.
The MDI Biological Laboratory has been transformed in the 21st century and is recognized by the international science community and the National Institutes of Health (NIH) as a world leader in regenerative medicine and aging research.
In Bar Harbor, MDI Biological Laboratory and its spinout company, Novo Biosciences, said they have identified a potential drug candidate derived from a shark that may restore heart muscle function after a heart attack. They described how the drug candidate, MSI-1436, regenerates heart muscle tissue in zebrafish and mice in the journal Regenerative Medicine.
Quick healing is often seen as a superpower in comic books or movies, but it does have a basis in reality. While humans don’t have the ability to regrow entire body parts in the way starfish can, children have been known to regrow fingertips, provided they’ve got part of the nail left. Early on in life, we lose this ability and our super-healing genetic switch is turned off. But now, researchers at MDI Biological Laboratory in Maine have discovered a molecule which may be able to turn it ba…
The U.S. Department of Health and Human Services has called regenerative medicine the “vanguard of 21st century healthcare.” Regenerative medicine R&D efforts are focused largely on developing stem cell and tissue engineering therapies as a means to regenerate, replace or repair damaged tissues and organs. Despite over 15 years of extensive research, these approaches remain challenged by problems with efficacy, by their complexity and expense and by regulatory hurdles.
U.S. researchers claim to have identified a groundbreaking drug that could restore heart muscle function following a heart attack. A new study describes how MSI-1436, a naturally occurring compound, regenerates heart muscle tissue in zebrafish and mice. The animals are separated by 450 million years of evolution, raising hopes that the drug could help heal human hearts to…